Potential Role of New Therapies in Modifying Cardiovascular Risk in Overweight Patients with Metabolic Risk Factors

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Obesity

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/oby.2006.294PMID 16931496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size.

  2006cited by this paper
• Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

  2006cited by this paper
• The Gut and Energy Balance: Visceral Allies in the Obesity Wars

  2005cited by this paper
• Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.

  2005cited by this paper
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

  2005influential reference
• Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity.

  2005influential reference
• The effect of AOD9604 on weight loss in obese adults: Results of a randomized, double-blind, placebo-controlled, multicenter study

  2005cited by this paper
• The endocannabinoid system and its therapeutic exploitation

  2004cited by this paper
• Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats.

  2004cited by this paper
• Cannabinoid physiology and pharmacology: 30 years of progress.

  2004cited by this paper
• Appetite regulation: from the gut to the hypothalamus

  2004influential reference
• “What are the Yanks Doing?” The U.S. Experience with Implantable Gastric Stimulation (IGS) for the Treatment of Obesity — Update on the Ongoing Clinical Trials

  2004cited by this paper
• CCK1R agonists: a promising target for the pharmacological treatment of obesity.

  2003cited by this paper
• Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity.

  2003cited by this paper
• Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.

  2003cited by this paper
• The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

  2003cited by this paper
• Endocannabinoids and the regulation of body fat: the smoke is clearing.

  2003cited by this paper
• The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis.

  2003cited by this paper
• Gastric pacing for morbid obesity: plasma levels of gastrointestinal peptides and leptin.

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Ghrelin enhances appetite and increases food intake in humans.

  2001cited by this paper
• The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.

  2001cited by this paper
• The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice.

  2001cited by this paper
• Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.

  1999cited by this paper
• Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.

  1998cited by this paper
• In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum

  1998cited by this paper
• Cholecystokinin decreases food intake in rats. 1973.

  1997cited by this paper
• Cholecystokinin Decreases Food Intake in Rats1

  1997cited by this paper
• Characterization and inhibition of a cholecystokinin-inactivating serine peptidase

  1996cited by this paper
• Cholecystokinin decreases food intake in rats.

  1973cited by this paper

• CCK1R2R-/- ameliorates myocardial damage caused by unpredictable stress via altering fatty acid metabolism

  2023cites this paper
• Gastric Pacing / Electrical Stimulation and Gastric Per Oral Endoscopic Myotomy

  2019cites this paper
• Milk Protein Hydrolysates and Bioactive Peptides

  2016cites this paper
• Nanocarriers and the delivered drug: effect interference due to intravenous administration.

  2014cites this paper
• Milk protein hydrolysates activate 5-HT(2C) serotonin receptors: influence of the starting substrate and isolation of bioactive fractions.

  2013cites this paper
• The Border of Internal Medicine and Metabolic Surgery

  2012cites this paper
• The neurohormonal regulation of energy intake in relation to bariatric surgery for obesity.

  2010cites this paper
• (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.

  2009cites this paper
• Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Sponsorship

  2009cites this paper
• New Hydrophobicity Constants of Substituents in Pyrazine Rings Derived from RP-HPLC Study

  2008cites this paper
• Increased broiler muscle carnosine and anserine following histidine supplementation of commercial broiler feed concentrate

  2008cites this paper
• THE ENDOCANNABINOID SYSTEM AND CARDIOVASCULAR DISEASE

  2008cites this paper
• Hyperglycemia, Hypertension, and Dyslipidemia in Type 2 Diabetes Mellitus: Goals for Diabetes Management

  2008cites this paper
• Insulin Resistance Syndrome and Its Vascular Complications

  2007cites this paper
• How current Guidelines for obesity underestimate risk in certain ethnicities and overestimate risk in others

  2007cites this paper
• Basal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.

  2007cites this paper
• United States Patent ( 10 ) Patent No . : US 8 , 153 , 621 B 2

  year unknowncites this paper